| 摘要 |
FIELD: medicine, ophthalmology. SUBSTANCE: invention describes composition used for treatment of glaucoma and intraocular hypertensions and the use of EP1 agonists of prostanoid receptors that reduce intraocular pressure effectively but do not or reduce the pigmentation effect or iris. Prostaglandin analog as a EP1 selective agonist is applied on eye topically. Invention provides attenuation of adverse effect expressing as melanogenesis. EFFECT: enhanced and valuable properties of prostaglandins. 4 cl, 5 tbl, 7 ex
|
